Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

Cancer Nanomedicine: Advanced Nanocarrier Systems, Targeted Drug Delivery, Theranostics, and Emerging Strategies for Precision Oncology

Cancer remains one of the leading causes of morbidity and mortality worldwide despite substantial advances in diagnosis and treatment. Conventional therapeutic approaches, including chemotherapy, radiotherapy, surgery, and immunotherapy, are often limited by poor tumor selectivity, systemic toxicity, multidrug resistance, and inadequate drug accumulation at the disease site. Nanomedicine has emerged as a transformative strategy in oncology, offering innovative solutions for targeted drug delivery, improved pharmacokinetics, enhanced therapeutic efficacy, and reduced off-target toxicity. Owing to their unique physicochemical properties, nanoparticles can be engineered to overcome biological barriers associated with tumor progression and facilitate precise delivery of therapeutic and diagnostic agents. This review comprehensively discusses the fundamental principles of cancer nanomedicine, including tumor biology, barriers to drug delivery, and critical design considerations for nanocarrier development. Various classes of nanomaterials, including polymeric nanoparticles, lipid-based systems, inorganic nanomaterials, and emerging biomimetic platforms, are examined with respect to their structural characteristics, therapeutic applications, and translational potential. Particular emphasis is placed on tumor-targeting strategies, encompassing passive, active, and microenvironment-responsive approaches, as well as on the development of smart stimuli-responsive nanocarriers capable of controlled, site-specific drug release. Furthermore, recent advances in nanotechnology-enabled chemotherapy, combination therapy, gene and RNA delivery, immuno-nanomedicine, and theranostic platforms are highlighted. The integration of diagnostic imaging and therapeutic functions within multifunctional nanocarriers has enabled real-time monitoring of treatment response and personalized cancer management. In addition, challenges associated with safety, toxicity, large-scale manufacturing, regulatory approval, and clinical translation are critically evaluated. Emerging innovations, including artificial intelligence-driven nanocarrier design, biomimetic nanomedicines, and precision oncology approaches, are also explored as future directions for the field.Overall, cancer nanomedicine has evolved from a simple drug-delivery concept into a multifunctional therapeutic platform integrating targeted therapy, molecular imaging, immunomodulation, gene therapy, and personalized medicine. Continued interdisciplinary collaboration and technological innovation are expected to accelerate the clinical translation of next-generation nanomedicines, ultimately improving treatment outcomes and advancing precision cancer care.

Nanocarriers in Ovarian Cancer: Targeted Drug Delivery, Theranostics, and Immunomodulation

Enhancing Cancer Patient Outcomes using Theranostic Nanomedicine: Advances, Challenges, and Future Prospects.

Theranostic nanomedicine integrates diagnostic and therapeutic functions into a single nanoparticle, allowing clinicians to image a tumor and treat it with the same agent. The logic is simple: instead of administering separate compounds to patients for imaging and treatment, both functions are delivered concurrently. Nanoparticles reach tumor tissue mainly through the EPR effect; leaky vasculature and poor lymphatic drainage cause passive accumulation. Attaching ligands for receptors overexpressed on tumor cells adds a second layer of selectivity. Liposomes, dendrimers, polymeric micelles, and metal nanoparticles have all been adapted for drug-imaging combinations, each with different loading and surface modification options. Protein corona remains a frustrating obstacle. Serum proteins adsorb onto nanoparticle surfaces and throw off targeting, which has pushed groups toward more elaborate designs. D-type peptide-modified nanoparticles withstand enzymatic degradation better than standard L-type versions; oncolytic peptide-based systems have also shown immune-activating effects alongside direct cytotoxicity. Stimulus-responsive release pH, redox, or light-triggered continues to attract attention as a way to limit off-target exposure. However, most programmes fail to progress beyond clinical translation. Tumor heterogeneity means a nanoparticle optimized for one patient's receptor profile may be unremarkable in another patient's profile. Regulators have not agreed on how to classify combination nano-diagnostic-therapeutic products, so approval pathways are unclear. Large-scale synthesis, reproducible manufacturing, and harmonized evaluation guidelines all remain to be established before clinical translation can proceed.

Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics

Next-generation personalized cancer vaccines are advancing the transition from reactive treatment to proactive, precision-controlled cancer immunotherapy, and when integrated with artificial intelligence for antigen selection and multiomics for patient stratification, these platforms accelerate vaccine design and improve precision.

Mechanistic advances in nanomedicine, nucleic acid therapies, and AI-driven research on cervical cancer.

A translational framework for overcoming key barriers in pharmaceutical intervention design for oncology applications is outlined, integrating drug delivery engineering, molecular biopharmaceutics, and computational optimization.

Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges

Abstract The field of nanotechnology has demonstrated considerable potential in the diagnosis and treatment of prostate cancer, particularly through the use of prostate-specific membrane antigen (PSMA)-targeted platforms and tumor microenvironment (TME)-responsive systems. In the context of diagnosis, nanoparticle-based molecular imaging probes have been shown to enhance detection sensitivity and specificity. These probes include superparamagnetic iron oxide, which is utilized in magnetic resonance imaging, and near-infrared fluorescent nanomicelles. Additionally, nanostructured liquid biopsy systems have demonstrated the capability to capture circulating tumor cells, exosomes, and circulating tumor DNA with high sensitivity, facilitating non-invasive genotyping and treatment monitoring. In the field of therapeutics, PSMA-targeted liposomes, polymeric nanoparticles, and inorganic nanocarriers have demonstrated efficacy in enhancing the delivery of chemotherapeutics, gene-editing tools (eg, CRISPR/Cas9, siRNA), and immunomodulators. These delivery mechanisms are equipped with TME-responsive release mechanisms (eg, pH, enzyme, redox) that enable the spatiotemporal control of drug release. Nanotechnology offers multi-level strategies to overcome multidrug resistance in castration-resistant prostate cancer, including PROTAC-mediated protein degradation, ferroptosis induction, and synergistic chemo-immunotherapy. Multifunctional theranostic nanoplatforms integrating imaging and therapy enable real-time efficacy assessment and personalized treatment adaptation. Emerging green synthesis approaches that utilize agricultural byproducts and bio-inspired platforms (eg, cell membrane-coated nanoparticles) present sustainable and biocompatible alternatives. Concurrently, artificial intelligence (AI) holds the potential to expedite the design of nanocarriers. Despite the advancement of several nanomedicines to clinical trials, significant translational barriers persist. These include heterogeneous PSMA expression (15–37% of castration-resistant prostate cancer cases are PSMA-negative), suboptimal enhanced permeability and retention effect in humans, long-term safety concerns, manufacturing hurdles, and regulatory gaps. This narrative review methodically examines the applications of nanotechnology in prostate cancer. It critically analyzes the clinical translation challenges encountered during clinical trials and discusses future directions, including smart responsive systems, multimodal immunotherapy, and AI-assisted nanomedicine design.